Rosuzet 20 mg / 10 mg film-coated tablets
Rosuzet 20 mg / 10 mg is a new combination preparation from Aristo Pharma GmbH, which can be used at the same time with diet as a replacement therapy for the treatment of primary hypercholesterolemia in adult patients, if the patients are adequately controlled on the individual substances. Rosuzet is a fixed-dose combination containing 20 mg rosuvastatin per tablet, as rosuvastatin chemical and 10 mg ezetimibe. Aristo already has another combination medicine rosuvastatin / ezetimibe Rosuzet 10 mg / 10 mg film-coated tablets
ORENCIA® 50- / 87.5 mg solution for injection in a pre-filled syringe
Orencia is used in combination with methotrexate (MTX) for the treatment of moderate to severe active rheumatoid arthritis in adults who have inadequately responded to previous treatment with one or more anti-inflammatory drugs, including methotrexate or a tumor necrosis factor (TNF) alpha, and Treatment of highly active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. In addition, it can be used alone or in combination with methotrexate (MTX) for the treatment of active psoriatic arthritis (PsA) in adult patients who have inadequately responded to previous DMequilibreplus.coms, including methotrexate and for whom additional systemic therapy is not required for psoriatic skin lesions . In combination with methotrexate for the treatment of moderate to severely active polyarticular juvenile idiopathic arthritis (pJIA) in pediatric patients> 2 years of age when response to previous DMequilibreplus.com therapy, including MTX, was insufficient. Orencia 50 and Orencia 87.5 mg represent the new strengths of Orencia already available on the Bristol-Myers Squibb GmbH & Co. market. KGaA. Orencia contains the active ingredient abatacept.
Waylivra 285 mg solution for injection in a pre-filled syringe
The new medicine Akcea Therapeutics Germany GmbH contains the active substance Volanesorsen. Wylivra is used for adjunctive treatment with diet in adult patients with genetically confirmed family chylomicronemia syndrome (FCS) and at high risk of pancreatitis, where nutritional response and therapy to reduce triglyceride were inadequate.